Insta
First Batch Of DRDO And Dr Reddy's 2-DG COVID-19 Drug To Be Launched Early Next Week
DRDO Logo (Pic Via Wikipedia)
In a boost for the national efforts against the COVID-19 pandemic, the first batch of 2-deoxy-D-glucose (2-DG) drug will be launched next week, reports Livemint.
The drug has been developed by the DRDO lab, Institute of Nuclear Medicine and Allied Sciences, in collaboration with Hyderabad based pharmaceutical major Dr Reddy’s Laboratories to treat moderate to severe Covid-19 cases.
The 2-DG has been cleared by the Drug Controller General of India (DCGI) for emergency use in the treatment of Covid-19 patients earlier last week.
The first batch will comprise of 10,000 doses of 2-DG. It will be administered to patients as an adjunct therapy or an alternative treatment to assist the primary treatment.
A DRDO statement had earlier said that the clinical trial showed that the drug helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints in the efficacy trends.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
